Form 4: Kymera COO Executes Pre-Planned Stock Sales

Kymera Therapeutics' Chief Operating Officer, Jeremy G. Chadwick, executed pre-planned transactions involving the exercise of stock options and subsequent sale of common stock in late March and early April 2026.

Summary

• Chief Operating Officer Jeremy G. Chadwick engaged in pre-planned transactions under a Rule 10b5-1 trading plan established on December 10, 2025.
• On March 31, 2026, Chadwick exercised options to acquire 7,600 shares of common stock at $29.64 per share and subsequently sold these 7,600 shares at a weighted average price of $85.3792.
• On April 1, 2026, Chadwick exercised options to acquire 14,640 shares of common stock at $29.64 per share.
• On April 1, 2026, Chadwick sold 13,540 shares at a weighted average price of $85.4144 and an additional 1,100 shares at $86.05.
• Following these transactions, Chadwick's direct beneficial ownership of common stock remained at 61,202 shares.
• The stock options exercised had an initial vesting of 25% on May 22, 2024, with the remainder vesting monthly over 36 months, expiring on May 22, 2033.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While insider selling can sometimes be a concern, the execution under a 10b5-1 plan indicates a pre-scheduled transaction rather than a reaction to new negative information. The significant profit realized by the COO from option exercises also reflects positively on the company's stock performance over time.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned sales rather than a reaction to immediate company news.
• The sale prices of the common stock (ranging from $85.00 to $86.05) are significantly higher than the option exercise price ($29.64), indicating a substantial gain for the reporting person.

Negatives

• An insider selling shares, even if pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence, although this is mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it solely reports insider trading activities.

Management Comments

• These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan are common for executives to manage personal finances and diversify holdings without being subject to accusations of trading on material non-public information. While the sales represent a reduction in direct insider holdings, the pre-planned nature typically mitigates concerns about immediate negative sentiment regarding the company's prospects, especially in the biotechnology sector where executive compensation often includes significant equity components.

Comparison to Industry Standards

• This filing details routine insider transactions under a 10b5-1 plan, which is a standard practice across industries, including biotechnology.
• There are no specific company or project results to compare against global benchmarks in this type of filing.
• The exercise price of $29.64 compared to sale prices around $85 indicates a substantial personal gain for the executive, which is typical for long-term equity compensation plans in successful companies.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even if pre-planned, slightly increases the float and could be interpreted as a minor negative signal, though the 10b5-1 plan mitigates this. The significant profit realized by the executive from options exercise reflects positively on the stock's performance for long-term shareholders.
• Employees: The vesting schedule tied to continued employment is a standard incentive mechanism.

Next Steps

• The remaining unvested stock options will continue to vest in equal monthly installments over the remaining 36 months, subject to the reporting person's continued employment.

Key Dates

Recommendation

The filing details routine insider transactions under a Rule 10b5-1 plan, which are pre-scheduled and do not typically signal new information about the company's prospects. While the COO is selling shares, this is a common practice for executives to manage personal finances and diversify holdings. The significant profit realized from option exercises suggests past positive performance. Without additional company-specific news, this filing alone does not warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Rule 10b5-1, Executive Compensation, Jeremy G. Chadwick